CD274 and non-small cell lung carcinoma: The FDA has authorized the representative PD-1- or PD-L1-blocking antibodies nivolumab, pembrolizumab, and atezolizumab for the treatment of NSCLC patients, and pembrolizumab has been used as a first-line treatment for patients with PD-L1 levels ≥ 1%.